Aspire BioPharma is trading 10.78% up at $8.65, primarily on stronger biotech-sector sentiment.
- No clear company-specific announcement or filing dated August 25, 2026, was identified.
- Broader markets are also higher, while recent biotech momentum includes Moderna and Merck’s late-stage cancer-vaccine news.
- That news is supporting investor sentiment but is not specific to Aspire BioPharma.